Erasca, Inc. (ERAS)

In May 2025, Erasca announced clinical advancement and prioritization of its RAS-targeting franchise, IND clearances for ERAS-0015 and ERAS-4001, and strategic partnership opportunities for naporafenib, extending its cash runway into the second half of 2028; the company also reported a net loss of $31.0 million for Q1 2025. In June 2025, the company initiated the SEACRAFT-2 pivotal Phase 3 trial evaluating Naporafenib plus Trametinib in patients with NRAS-Mutant Melanoma. In August 2025, Erasca reported a widened loss for Q2 2025 and cash, cash equivalents, and marketable securities of $386.7 million, expected to fund operations into the second half of 2028. In September 2025, BofA double downgraded Erasca to Underperform. In October 2025, Stifel initiated coverage of Erasca with a Buy recommendation, Weiss Ratings issued a Sell (D-) rating, and Seeking Alpha downgraded Erasca to Hold, citing a shift in focus to novel RAS inhibitors and intense competition; Erasca also announced an update on its ongoing Phase 1 clinical study for ERAS-0015.

As a clinical-stage biopharmaceutical company, Erasca, Inc. does not currently generate significant revenue from product sales or ongoing services, therefore, demand seasonality for its products and services is not applicable.

Erasca, Inc. is a clinical-stage precision oncology company focused on developing therapies for RAS/MAPK pathway-driven cancers. The company's mission is to erase cancer by targeting the RAS/MAPK pathway, which is implicated in approximately 30% of all human cancers. Erasca's financial structure is primarily supported by raised capital rather than product sales. Key pipeline candidates include Naporafenib (ERAS-601), an oral ERK1/2 inhibitor (ERAS-007), a SHP2 inhibitor (ERAS-601), a pan-RAS molecular glue (ERAS-0015), and a pan-KRAS inhibitor (ERAS-4001).

Erasca, Inc. is headquartered in San Diego, California, United States. Its operations are focused on research and development, with clinical trials managed globally.

Erasca's brand reputation has been influenced by clinical advancements and varying analyst sentiments. The company has been recognized for its strategic focus on the RAS/MAPK pathway and the advancement of its pipeline candidates. Positive analyst initiations and upgrades suggest a favorable view from some in the financial community. However, downgrades and "Sell" ratings indicate some skepticism, particularly concerning competition in the RAS inhibitor space and the long timelines for data. No specific events directly impacting its general public reputation were found beyond the typical fluctuations associated with a clinical-stage biotech company's progress and financial performance.

As of recent reports, 67.78% of Erasca's stock is owned by institutional investors and hedge funds. Major institutional owners include Frazier Life Sciences Management L.P., VR Adviser LLC, T. Rowe Price Investment Management Inc., Affinity Asset Advisors LLC, and Nuveen LLC.